Cargando…
The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
PURPOSE: To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients. PATIENTS AND METHODS: A total of 363 lung cancer patients were recruited in this study. All of them received at...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458023/ https://www.ncbi.nlm.nih.gov/pubmed/34566424 http://dx.doi.org/10.2147/PGPM.S325788 |
_version_ | 1784571233949450240 |
---|---|
author | He, Jia Wang, Zhan Wang, Ying Zou, Ting Li, Xiang-Ping Cao, Lei Chen, Juan |
author_facet | He, Jia Wang, Zhan Wang, Ying Zou, Ting Li, Xiang-Ping Cao, Lei Chen, Juan |
author_sort | He, Jia |
collection | PubMed |
description | PURPOSE: To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients. PATIENTS AND METHODS: A total of 363 lung cancer patients were recruited in this study. All of them received at least two cycles of platinum-based chemotherapy. We used unconditional logistic regression analysis to assess the associations of 39 single nucleotide polymorphisms in WISP1 gene with platinum-based chemotherapy prognosis. RESULTS: The results indicated that patients carried rs2929973 GT or GG genotypes had increased risk of disease progression (HR = 0.712, 95% CI = 0.553–0.916, P = 0.015). Patients with rs2977551 TT genotype had a significantly decreased risk of progression-free survival than patients carrying CT or CC genotype (HR = 0.723, 95% CI = 0.561–0.932, P = 0.032) and overall survival (HR = 0.725, 95% CI = 0.552–0.913, P = 0.045). For rs2977549, patients carrying TT genotype had a significantly longer progression-free survival than patients with CC or CT genotypes (HR = 0.708, 95% CI = 0.550–0.912, P = 0.017). Among of them, rs16904853, rs10956697, rs2929965, rs2929973, rs7828685, rs2977551 and rs2977549 were related to progression-free survival, and rs10956697 and rs2977551 were related to overall survival in subgroup analyses, respectively. CONCLUSION: WISP1 rs2929973, rs2977551 and rs2977549 may be contributed to a potential candidate biomarker for prediction of platinum-based chemotherapy prognosis in lung cancer patients. |
format | Online Article Text |
id | pubmed-8458023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84580232021-09-23 The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy He, Jia Wang, Zhan Wang, Ying Zou, Ting Li, Xiang-Ping Cao, Lei Chen, Juan Pharmgenomics Pers Med Original Research PURPOSE: To investigate the relationships between Wnt1 inducible signaling pathway protein 1 (WISP1) polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients. PATIENTS AND METHODS: A total of 363 lung cancer patients were recruited in this study. All of them received at least two cycles of platinum-based chemotherapy. We used unconditional logistic regression analysis to assess the associations of 39 single nucleotide polymorphisms in WISP1 gene with platinum-based chemotherapy prognosis. RESULTS: The results indicated that patients carried rs2929973 GT or GG genotypes had increased risk of disease progression (HR = 0.712, 95% CI = 0.553–0.916, P = 0.015). Patients with rs2977551 TT genotype had a significantly decreased risk of progression-free survival than patients carrying CT or CC genotype (HR = 0.723, 95% CI = 0.561–0.932, P = 0.032) and overall survival (HR = 0.725, 95% CI = 0.552–0.913, P = 0.045). For rs2977549, patients carrying TT genotype had a significantly longer progression-free survival than patients with CC or CT genotypes (HR = 0.708, 95% CI = 0.550–0.912, P = 0.017). Among of them, rs16904853, rs10956697, rs2929965, rs2929973, rs7828685, rs2977551 and rs2977549 were related to progression-free survival, and rs10956697 and rs2977551 were related to overall survival in subgroup analyses, respectively. CONCLUSION: WISP1 rs2929973, rs2977551 and rs2977549 may be contributed to a potential candidate biomarker for prediction of platinum-based chemotherapy prognosis in lung cancer patients. Dove 2021-09-18 /pmc/articles/PMC8458023/ /pubmed/34566424 http://dx.doi.org/10.2147/PGPM.S325788 Text en © 2021 He et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research He, Jia Wang, Zhan Wang, Ying Zou, Ting Li, Xiang-Ping Cao, Lei Chen, Juan The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title | The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title_full | The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title_fullStr | The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title_full_unstemmed | The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title_short | The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy |
title_sort | effects of wisp1 polymorphisms on the prognosis of lung cancer patients with platinum-based chemotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458023/ https://www.ncbi.nlm.nih.gov/pubmed/34566424 http://dx.doi.org/10.2147/PGPM.S325788 |
work_keys_str_mv | AT hejia theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT wangzhan theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT wangying theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT zouting theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT lixiangping theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT caolei theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT chenjuan theeffectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT hejia effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT wangzhan effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT wangying effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT zouting effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT lixiangping effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT caolei effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy AT chenjuan effectsofwisp1polymorphismsontheprognosisoflungcancerpatientswithplatinumbasedchemotherapy |